Review on prevention of cardiovascular disease

Avinash Avinash; Kiran kumar C; Venkatesh P

doi:10.37022/jpmhs.v4i2.69

Authors

Avinash B.Pharmacy final year student, Jagan’s Institute of Pharmaceutical Sciences, Nellore
C.Kiran kumar Associate Professor, Dept.of Pharmacy Practice, Jagan’s Institute of Pharmaceutical Science, Nellore
P. Venkatesh Principal Jagan’s Institute of Pharmaceutical Science, Nellore

DOI:

https://doi.org/10.37022/jpmhs.v4i2.69

Keywords:

Cardiovascular disease,, prevention, causes

Abstract

Cardiovascular disease is a significant and ever-growing problem in the united kingdom, accounting for nearly one third of particular and pressing interest as developed countries experienced a change in life style. With an ageing population and increasing cost of chronic medication care, primary prevention of cardiovascular disease is an important target for healthcare provides. The new international guidelines have been produced regarding hypertension and lipid lowering therapies. Firstly it discusses common types of cardiovascular diseases common types of cardiovascular around the global and their causes. Secondly, it analyses different risk factors associated with cardiovascular diseases and then discusses incoming technological trends in cardiovascular disease prediction and finally provides an insight into the importance of prevention of cardiovascular disease.

Downloads

Download data is not yet available.

References

Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004;89:2595-600.

Jack Stewart1 , Katherine Addy2 , Sarah Campbell3 and Peter Wilkinson, Primary prevention of cardiovascular disease: Updated review of contemporary guidance and literature, Volume 9: 1–12 2020.

Harpal S Buttar DVM PhD, Timao Li PhD, Nivedita Ravi BSc, Prevention of cardiovascular diseases: Role of exercise, dietary interventions, obesity and smoking cessation .

Maarten J. G. Leening1,2,3, M. Arfan Ikram1 , Primary prevention of cardiovascular disease: The past, present, and future of blood pressure- and cholesterol-lowering treatmentS: March 20, 2010.

Sachith Paramie Karunathilake and Gamage Upeksha Ganegoda, Secondary Prevention of Cardiovascular Diseases and Application of Technology for Early Diagnosis , 2018.

Wilkins E, Wilson L, Wickramasinghe K, Bhatnagar P, et al. European Heart Network. European Cardiovascular Disease Statistics 2017. Brussels: European Heart Network.

Yusuf S, Hawken S, Oˆunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937–952.

Lavie C, O’Keefe J, Church T, et al. The role of physical fitness in cardiovascular disease prevention. The Medical Roundtable General Medicine Edition 2020.

Liu Y, Lee DC, Li Y, et al. Associations of resistance exercise with cardiovascular disease morbidity and mortality. Med Sci Sports Exerc 2019; 51: 499–508.

Eijsvogels TM, Molossi S, Lee D, et al. Exercise at the extremes: the amount of exercise to reduce cardiovascular events. J Am Coll Cardiol 2016; 67: 316–329.

NICE. Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE Guideline CG181 2016.

Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol 2014; 63: 2960–2984.

Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387: 957–967.

Thomopoulos C, Parati G and Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. J Hypertens 2017; 35: 2150–2160.

SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373: 2103–2116.

Tervahauta M, Pekkanen J, Enlund H, et al. Change in blood pressure and 5-year risk of coronary heart disease among and mortality in patients with manifest vascular disease: J-curve revisited. Hypertension 2012; 59: 14–21.

Kang YY and Wang JG. The J-Curve phenomenon in hypertension. Pulse (Basel) 2016; 4: 49–60.

Bundy JD, Li C, Stuchlik P, et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol 2017; 2: 775–781.

Wiysonge CS, Bradley HA, Volmink J, et al. Betablockers for hypertension. Cochrane Datab Syst Rev 2017; 1(1). DOI: 10.1002/14651858.CD002003.pub5

. . Sheppard JP, Stevens S, Stevens R, et al. Benefits and harms of antihypertensive treatment in low-risk patients with mild hypertension. JAMA Intern Med 2018; 178: 1626–1634.

King P, Peacock I and Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol 1999; 48: 643–648.

ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–2572. 89. Kirkman MS, Mahmud H and Korytkowski MT. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes mellitus. Endocrinol Metab Clin North Am 2018; 47: 81–96.

Herman ME, O’Keefe JH, Bell DS, et al. Insulin therapy increases cardiovascular risk in type 2 diabetes. Prog Cardiovasc Dis 2017; 60: 422–434.

Genuth S. Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulindependent diabetes mellitus. Ann Intern Med 1996; 124: 104–109.

Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380: 347–357.